Literature DB >> 11231704

Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.

K Bork1, S E Barnstedt.   

Abstract

BACKGROUND: Hereditary angioedema (HAE) is an autosomal dominant disease (Mendelian Inheritance in Man 106100) caused by an inherited deficiency of C1 inhibitor (C1-INH) function. The clinical symptoms include skin swelling, abdominal pain, and life-threatening episodes of upper airway obstruction. We evaluated the efficacy of C1-INH concentrate for treating sudden airway compromise.
METHODS: A series of 95 patients with HAE and a functional deficiency of C1-INH belonging to 59 families underwent screening for laryngeal edema. Double-blind treatment of randomized patients was not justifiable because of the life-threatening nature of this condition. Efficacy was evaluated by determining the interval from injection of C1-INH concentrate to the beginning of resolution of symptoms. The mean duration of episodes of laryngeal edema was compared in treated and untreated patients. Clinical information was obtained from emergency department physicians, the hospitals involved, reports of the general practitioners, and patients and their relatives.
RESULTS: Forty-two patients had 517 episodes of laryngeal edema. Eighteen patients received 500- or 1000-U injections of C1-INH concentrate in 193 episodes. The C1-INH concentrate was effective in all laryngeal edemas. The interval from injection to interruption in progress of symptoms ranged from 10 minutes to 4 hours (mean +/- SD, 42.2 +/- 19.9 minutes). The mean +/- SD duration of laryngeal edema was 15.3 +/- 9.3 hours in patients who received C1-INH concentrate and 100.8 +/- 26.2 hours in those who did not.
CONCLUSIONS: Injected C1-INH concentrate is highly and rapidly effective in the treatment of laryngeal edema of HAE. Relief and resolution of symptoms begins 30 to 60 minutes after injection, and duration of the upper airway obstruction is substantially reduced.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231704     DOI: 10.1001/archinte.161.5.714

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  39 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Current management options for hereditary angioedema.

Authors:  Konrad Bork
Journal:  Curr Allergy Asthma Rep       Date:  2012-08       Impact factor: 4.806

3.  Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate.

Authors:  Peter J Gorman
Journal:  Can Fam Physician       Date:  2008-03       Impact factor: 3.275

Review 4.  Hereditary angioedema in childhood: an approach to management.

Authors:  Didier G Ebo; Marjoke M Verweij; Kathleen J De Knop; Margo M Hagendorens; Chris H Bridts; Luc S De Clerck; Wim J Stevens
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

5.  Acquired angioedema.

Authors:  Marco Cicardi; Andrea Zanichelli
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

Review 6.  Management of acute attacks of hereditary angioedema: potential role of icatibant.

Authors:  Hilary J Longhurst
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

7.  On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience.

Authors:  Emel Aygören-Pürsün; Inmaculada Martinez-Saguer; Eva Rusicke; Thomas Klingebiel; Wolfhart Kreuz
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

8.  HAE international home therapy consensus document.

Authors:  Hilary J Longhurst; Henriette Farkas; Timothy Craig; Emel Aygören-Pürsün; Claire Bethune; Janne Bjorkander; Konrad Bork; Laurence Bouillet; Henrik Boysen; Anette Bygum; Teresa Caballero; Marco Cicardi; John Dempster; Mark Gompels; Jimmy Gooi; Sofia Grigoriadou; Ursula Huffer; Wolfhart Kreuz; Marcel M Levi; Janet Long; Inmaculada Martinez-Saguer; Michel Raguet; Avner Reshef; Tom Bowen; Bruce Zuraw
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

9.  Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema.

Authors:  Timothy J Craig; Richard L Wasserman; Robyn J Levy; Againdra K Bewtra; Lynda Schneider; Flint Packer; William H Yang; Heinz-Otto Keinecke; Peter C Kiessling
Journal:  J Clin Immunol       Date:  2010-07-16       Impact factor: 8.317

10.  The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q.

Authors:  Maria Grazia De Simoni; Emanuela Rossi; Claudio Storini; Simone Pizzimenti; Cinara Echart; Luigi Bergamaschini
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.